BioNxt Announces Shares for Debt Settlement

About this update from Bionxt Solutions Inc

[{"type":"text","content":"NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES","length":98,"tagName":"p"},{"type":"text","content":"VANCOUVER, BC / ACCESS Newswire / September 12, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:4XT) announces the Company has entered into a debt settlement agreement with an arm's length creditor (the "Creditor") related to an aggregate of $225,010 outstanding debt (the "Debt") owing for services provided by the Creditor to the Company. In full satisfaction and settlement of the Debt, the Company will: (i) issue an aggregate of 112,505 common shares in the capital of the Company (the "Debt Shares") at a deemed price of CAD$1.00 per Debt Share and (ii) make a cash payment of $112,505 to the Creditor (the "Debt Settlement").","length":733,"tagName":"p"},{"type":"text","content":"The Debt Shares issued in connection with the Debt Settlement will be subject to a statutory four month and one day hold period, in accordance with the policies of the Canadian Securities Exchange ("CSE") and applicable Canadian securities laws. The issuance of the Debt Shares and completion of the Debt Settlement is subject to certain conditions including the receipt of all necessary regulatory approvals, including the approval of the CSE.","length":454,"tagName":"p"},{"type":"text","content":"About BioNxt Solutions Inc.BioNxt Solutions Inc. is a bioscience innovator focused on next‐generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin‐Film), Transdermal (Skin Patch), and Oral (Enteric‐Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity. With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient‐centric solutions that enhance treatment outcomes worldwide.","length":751,"tagName":"p"},{"type":"text","content":"BioNxt is listed on the Canadian Securities Exchange: BNXT, OTCQB Markets:BNXTF and trades in Germany under WKN:...

More updates from Bionxt Solutions Inc